The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
- Study type
- Clinical guideline
- Study name
- WHO-HAEM5 (Lymphoid)
- Design
- Review and presentation of a classification (fifth edition of the World Health Organization classification of lymphoid neoplasms)
- Source
- Leukemia · 2022
In plain words
The World Health Organization publishes an official list for naming and grouping cancers and diseases of lymphoid cells (such as lymphomas), which pathologists and doctors use when making a diagnosis. This article introduces the fifth edition of this list, in which the names or diagnostic criteria of some diseases have changed. If you see a different name or subtype in your pathology report, your treating doctor can explain what the change means.
Clinical significance and place in guidelines
This classification is the diagnostic reference for lymphoid neoplasms and affects how pathology is reported and how diseases are named. According to the abstract, the main changes include a hierarchical structure, revised nomenclature, revised diagnostic criteria, deletion and addition of entities, and the addition of germline predisposition syndromes. Details of each change and the extent of its adoption in clinical guidelines should be checked in the full text and authoritative guidelines.
Limitations
This article is a diagnostic classification, not a treatment trial; the abstract gives no data on clinical outcomes. Myeloid and histiocytic neoplasms are covered in a separate article. An erratum to this article was published in Leukaemia 2023.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.